AbbVie Inc (ABBV)vsTransMedics Group Inc (TMDX)
ABBV
AbbVie Inc
$264.34
-0.29%
HEALTHCARE · Cap: $454.36B
TMDX
TransMedics Group Inc
$85.29
+1.66%
HEALTHCARE · Cap: $3.03B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9532% more annual revenue ($64.39B vs $668.47M). TMDX leads profitability with a 22.7% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TMDX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.34
$112.18 premium
Margin of Safety
+53.7%
Fair Value
$287.78
Current Price
$85.29
$202.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 35 in profit
Keeps 23 of every $100 in revenue as profit
Growing faster than its price suggests
Revenue surging 20.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Distress zone — elevated risk
Elevated debt levels
Earnings declined 55.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : TMDX
The strongest argument for TMDX centers on Return on Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 22.7% and operating margin at 12.5%. Revenue growth of 20.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : TMDX
The primary concerns for TMDX are Altman Z-Score, Debt/Equity, EPS Growth. Debt-to-equity of 1.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while TMDX is a growth play — different risk/reward profiles.
TMDX carries more volatility with a beta of 1.88 — expect wider price swings.
TMDX is growing revenue faster at 20.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 62/100) and 10.2% revenue growth. TMDX offers better value entry with a 53.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
TransMedics Group Inc
HEALTHCARE · MEDICAL DEVICES · USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?